T Cell Receptor-Engineered T Cells Therapy: Strategy for Targeting Tumor Driver Antigen

The clinical treatments of tumors have been changing in decades. In addition to such traditional approaches as clinical surgery, radiotherapy, chemotherapy and targeting therapy, tumor immunotherapy has also shown strong anti-tumor efficacy, and has become one of the hot spots in anticancer clinical research. Based on the recent exploration on cancer antigens, several crucial driver mutations and their targeting T cells were identified. Moreover, the driver mutation antigen-specific T cells effectively induced an anti-tumor response,revealing the potential of anti-tumor clinical strategy via T cell receptor-engineered T cell (TCR-T) immunotherapy, which based on the T cell recognition of tumor driver antigens. This paper summarizes the recent progress of tumor driver mutation antigens and the strategy of TCR-T immunotherapy targeting these antigens, so as to provide a theoretical basis for further clinical research on TCR-T tumor immunotherapy.